Corporate Technology Transactions

THE PRACTICE

The firm’s Technology & Innovation Group specialises in advising innovative technology, life sciences and venture-backed companies on corporate transactions. We advise emerging and established companies on a multitude of corporate matters, including company formation and establishment in Ireland, equity structures and incentive schemes, fundraisings and exits.

Our Corporate Technology Transactions practice sits in the Technology & Innovation Group but is a multidisciplinary one, drawing in expertise from relevant areas such as Corporate (M&A), Intellectual Property, Employment, Tax, Life Sciences, Fintech and Company Compliance and Corporate Governance. Our practice works closely with our Inward Investment Group advising international clients on setting up corporate structures in Ireland both to service the local market and also as part of multi-jurisdictional corporate structures.On the venture capital side, we regularly partner with US law firms and other international corporate advisers to simplify cross border venture capital transactions involving Irish incorporated companies by adapting US NVCA style investment documents to work under Irish Law (particularly where the venture capital investment is being introduced from US venture capital funds).

EXPERTISE

Our depth of experience enables us to provide high quality, strategic advice to our clients in the following areas:

  • Venture capital financing (both domestic and NVCA formats)
  • Venture debt transactions
  • Convertible loan notes and bridge financings
  • Company formation and equity structures
  • Share option and incentive schemes
  • ISO treatment for options granted to US based employees
  • Strategic warrant pools
  • “Partial Exits” and “Secondary Sales” in VC-backed companies prior to full exit
  • Exits (from mergers and acquisitions to IPOs)
  • Joint ventures and partnerships
  • Corporate governance
  • Tax and intellectual property driven corporate structures

EXPERIENCE

We have recently advised:

  • an Irish life sciences company on its $40 million Series A fund raising
  • an oncology research company raising $95 million from various venture capital investors
  • an Irish telecoms software company on an IPO
  • a biotechnology company on its $36 million fund raising
  • a medtech company on a venture debt transaction
  • an Irish fintech company on its $136 million Series A – D fund raisings
  • multiple clients on share award and other incentive schemes for both Irish and internationally based employees, contractors and other participants
  • a telecoms software provider raising over $90 million in three rounds of fund raisings
  • on the sale of an online payments company in an acquisition worth €115 million
  • a medical technology company on its $39 million in Series A and B financing
  • a life sciences company on a $25 million bridge financing
  • a software company on the sale of €12 million worth of shares by investors and other shareholders
  • an Irish medical device company on its $7.5 million Series B capital raising
  • various companies on the establishment of their corporate, tax and intellectual property structures in Ireland and overseas
  • numerous venture capital transactions involving investors such as Accel Partners, Arch, Audi Electronics Venture, Boston Scientific, Draper Esprit, General Catalyst, Goldman Sachs, IDG China, ISIF, Lightstone, Longevity Fund, Medtronic, New Enterprise Associates, Octopus, Oak Investment Partners, Polaris, Qualcomm Incorporated, Sierra Wireless, Stanford University, venBio, Woodford and others